Janssen Pharms Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?
JANSSEN PHARMS has fifty-eight approved drugs.
There are twenty-seven US patents protecting JANSSEN PHARMS drugs.
There are six hundred and twenty-seven patent family members on JANSSEN PHARMS drugs in sixty-three countries and ninety-seven supplementary protection certificates in seventeen countries.
Summary for Janssen Pharms
International Patents: | 627 |
US Patents: | 27 |
Tradenames: | 57 |
Ingredients: | 35 |
NDAs: | 58 |
Drugs and US Patents for Janssen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | SPORANOX | itraconazole | SOLUTION;ORAL | 020657-001 | Feb 21, 1997 | AA | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Janssen Pharms | INVOKAMET | canagliflozin; metformin hydrochloride | TABLET;ORAL | 204353-004 | Aug 8, 2014 | RX | Yes | Yes | 8,222,219 | See Plans and Pricing | See Plans and Pricing | ||||
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-002 | Mar 29, 2013 | RX | Yes | Yes | 7,943,582 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-004 | Oct 11, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
Janssen Pharms | RISPERDAL CONSTA | risperidone | INJECTABLE;INTRAMUSCULAR | 021346-003 | Oct 29, 2003 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Pharms | INVEGA SUSTENNA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022264-002 | Jul 31, 2009 | 5,254,556*PED | See Plans and Pricing |
Janssen Pharms | TOPAMAX | topiramate | TABLET;ORAL | 020505-002 | Dec 24, 1996 | 7,018,983*PED | See Plans and Pricing |
Janssen Pharms | TOPAMAX SPRINKLE | topiramate | CAPSULE;ORAL | 020844-003 | Oct 26, 1998 | 4,513,006*PED | See Plans and Pricing |
Janssen Pharms | INVEGA SUSTENNA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022264-002 | Jul 31, 2009 | 6,077,843*PED | See Plans and Pricing |
Janssen Pharms | ORTHO-NOVUM 7/7/7-21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 018985-001 | Apr 4, 1984 | 4,544,554 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
International Patents for Janssen Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 53274 | See Plans and Pricing |
Argentina | 047844 | See Plans and Pricing |
Russian Federation | 2493850 | See Plans and Pricing |
European Patent Office | 2896397 | See Plans and Pricing |
Japan | 2017528483 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1453521 | 122015000093 | Germany | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 |
1651658 | 164 1-2014 | Slovakia | See Plans and Pricing | PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115 |
1261606 | PA 2008 018, C 1261606 | Lithuania | See Plans and Pricing | PRODUCT NAME: RIVAROXABANUM; REGISTRATION NO/DATE: EU/1/07/472/001 - EU/1/08/472/008 20080930 |
1608344 | LUC00065 | Luxembourg | See Plans and Pricing | PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824 |
1651658 | CR 2014 00024 | Denmark | See Plans and Pricing | PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.